Abbott Laboratories (ABT) To Go Ex-Dividend on January 15th

Abbott Laboratories (NYSE:ABT) declared a quarterly dividend on Friday, December 12th. Shareholders of record on Thursday, January 15th will be paid a dividend of 0.63 per share by the healthcare product maker on Friday, February 13th. This represents a c) annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Thursday, January 15th. This is a 6.8% increase from Abbott Laboratories’s previous quarterly dividend of $0.59.

Abbott Laboratories has increased its dividend payment by an average of 0.1%per year over the last three years and has increased its dividend annually for the last 54 consecutive years. Abbott Laboratories has a payout ratio of 44.4% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Abbott Laboratories to earn $5.73 per share next year, which means the company should continue to be able to cover its $2.52 annual dividend with an expected future payout ratio of 44.0%.

Abbott Laboratories Trading Down 0.8%

NYSE:ABT opened at $123.60 on Tuesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The company has a market capitalization of $214.93 billion, a P/E ratio of 15.60, a P/E/G ratio of 2.09 and a beta of 0.72. The stock’s 50 day moving average price is $126.15 and its 200 day moving average price is $129.24. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.30. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The company had revenue of $11.37 billion during the quarter, compared to analysts’ expectations of $11.40 billion. During the same quarter in the previous year, the firm earned $1.21 earnings per share. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on ABT shares. Daiwa Capital Markets raised their price target on shares of Abbott Laboratories from $134.00 to $136.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 21st. Benchmark assumed coverage on Abbott Laboratories in a research note on Friday, October 10th. They set a “buy” rating and a $145.00 price target on the stock. Evercore ISI raised their price objective on Abbott Laboratories from $142.00 to $144.00 and gave the stock an “outperform” rating in a research report on Monday, January 5th. Jefferies Financial Group boosted their price objective on Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research report on Thursday, October 16th. Finally, William Blair raised Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $147.68.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.